AstraZeneca stock gains EU boost as JP Morgan sticks to Buy rating
Published on 09/01/2026 at 18:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca (ISIN US6549022043) stock is trading around 162.30 USD as of September 1, 2026, while investors weigh a new European Union approval for the company’s breast cancer drug regimen and a supportive analyst stance that sees upside from current levels.
EU approval strengthens oncology franchise
On September 1, 2026, AstraZeneca announced that Enhertu, developed with Daiichi Sankyo, in combination with pertuzumab, has been approved in the European Union as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, based on the DESTINY-Breast09 Phase III trial results.
According to AstraZeneca’s press release dated September 1, 2026, the Enhertu plus pertuzumab combination reduced the risk of disease progression or death by 44% versus the prior THP standard of care, with median progression-free survival of 40.7 months compared with 26.9 months, underscoring a tangible efficacy advantage for the new regimen.
The company also highlighted that following this approval, a milestone payment of 100 million USD is due from AstraZeneca to Daiichi Sankyo for the new first-line breast cancer indication, directly linking the clinical success to a sizeable financial obligation that investors must incorporate into their valuation of the oncology partnership.
Analyst view and valuation backdrop
Alongside the EU approval, market data compiled on September 1, 2026 show AstraZeneca stock at 162.30 USD, while average analyst targets cluster around 212.66 USD, implying roughly 31% upside if the consensus view is realized and giving context to the continued Buy recommendations from large houses.
A same-day overview reported that the stock closed at 162.30 USD, with JP Morgan maintaining a Buy rating and a higher price target compared with the prevailing London quotations, signalling that at least part of the market still sees the oncology pipeline and breast cancer advances as not fully reflected in today’s price.
Forecast data published on September 1, 2026 indicate that AstraZeneca’s net sales are projected to rise from 58,739 million USD in fiscal year 2025 to 63,250 million USD in 2026, an expected increase of about 7.7%, while EBITDA is forecast to grow from 19,476 million USD to 22,145 million USD over the same period, a rise of nearly 13.7%, suggesting that margins could continue to expand as high-value oncology products like Enhertu gain traction.
AstraZeneca stock and fundamentals at a glance
More detailed figures and historical data for AstraZeneca, including earnings and forecasts, can be accessed in the dedicated ISIN overview and on the company’s investor relations website.
Breast cancer portfolio in focus
Enhertu is positioned as a HER2-directed antibody drug conjugate that AstraZeneca and Daiichi Sankyo are already marketing globally in several breast cancer settings, and the new EU first-line approval fits into a broader strategy to move the drug earlier in the treatment pathway for HER2-positive metastatic disease.
Clinical data referenced in the DESTINY-Breast09 trial show that progression-free survival exceeding three years compares with roughly two years under the previous THP regimen, giving oncologists a more durable option and strengthening the commercial outlook for AstraZeneca’s breast cancer franchise.
AstraZeneca stock and market context
AstraZeneca PLC is listed on the New York Stock Exchange under the ticker AZN, with parallel listings in London and Stockholm; as of September 1, 2026, recent data point to a price of 162.30 USD and a corresponding valuation multiple of about 20.9 times projected 2026 earnings per share.
Analyst forecasts from the same dataset project net income for fiscal year 2026 at approximately 12,022 million USD, up from 10,225 million USD in 2025, an increase of around 17.6%, and free cash flow at 9,416 million USD, underlining that dividend capacity and debt reduction remain important elements of the equity story.
AstraZeneca key data
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Trading venue: NYSE
- Price (as of September 1, 2026): 162.30 USD
- Market capitalization: 250,000,000,000 USD (as of September 1, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
